MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge multiple intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Main trial objectives were To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory ai... https://fustin24568.bloggazza.com/30127186/new-step-by-step-map-for-imipenem